Aurobindo Pharma Gets 5 USFDA Observations for Unit-IV Facility
New Delhi: Aurobindo Pharma Limited has announced that the United States drug regulator has classified Unit-IV of its wholly owned subsidiary APL Healthcare Limited as "Voluntary Action Indicated" (VAI) following a regulatory inspection, indicating the closure of the inspection process.
According to the company, the facility located at Palchur village and part of Palepalem village in Naidupeta Mandal of SPSR Nellore district, Andhra Pradesh, was inspected by the U.S. Food and Drug Administration between December 8 and December 17, 2025. At the conclusion of the inspection, the regulator issued a Form 483 containing five observations.
The company stated that the facility has now received the Establishment Inspection Report (EIR) from the USFDA, which classifies the inspection outcome as “Voluntary Action Indicated.” With the issuance of the EIR, the inspection has been officially closed.
The update was shared with stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had earlier informed the exchanges about the inspection through its communication dated December 18, 2025.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.